Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ELTROMBOPAG Cause Thrombophlebitis superficial? 5 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Thrombophlebitis superficial have been filed in association with ELTROMBOPAG. This represents 0.1% of all adverse event reports for ELTROMBOPAG.

5
Reports of Thrombophlebitis superficial with ELTROMBOPAG
0.1%
of all ELTROMBOPAG reports
1
Deaths
3
Hospitalizations

How Dangerous Is Thrombophlebitis superficial From ELTROMBOPAG?

Of the 5 reports, 1 (20.0%) resulted in death, 3 (60.0%) required hospitalization, and 1 (20.0%) were considered life-threatening.

Is Thrombophlebitis superficial Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ELTROMBOPAG. However, 5 reports have been filed with the FAERS database.

What Other Side Effects Does ELTROMBOPAG Cause?

Platelet count decreased (968) Death (629) Drug ineffective (554) Product use in unapproved indication (303) Thrombocytopenia (262) Off label use (255) Headache (229) Pyrexia (229) Haemoglobin decreased (213) Pneumonia (204)

What Other Drugs Cause Thrombophlebitis superficial?

DROSPIRENONE\ETHINYL ESTRADIOL (160) LENALIDOMIDE (121) ETHINYL ESTRADIOL\ETONOGESTREL (93) RIVAROXABAN (82) YAZ (78) YASMIN (65) TESTOSTERONE (62) HUMAN IMMUNOGLOBULIN G (43) ADALIMUMAB (40) CAPECITABINE (29)

Which ELTROMBOPAG Alternatives Have Lower Thrombophlebitis superficial Risk?

ELTROMBOPAG vs ELTROMBOPAG OLAMINE ELTROMBOPAG vs ELUXADOLINE ELTROMBOPAG vs ELVITEGRAVIR ELTROMBOPAG vs EMAPALUMAB ELTROMBOPAG vs EMAPALUMAB-LZSG

Related Pages

ELTROMBOPAG Full Profile All Thrombophlebitis superficial Reports All Drugs Causing Thrombophlebitis superficial ELTROMBOPAG Demographics